In Brief: Noven Pharmaceuticals
Noven Pharmaceuticals: Miami-based company files NDA for transoral mucosal dental anesthetic delivery system, Noven announces May 30. The system incorporates lidocaine into a small, thin adhesive strip applied directly to the gum or elsewhere in the oral cavity for pain relief and numbing prior to injections, the company says. Noven will retain U.S. marketing rights and "is seeking licensing partners for foreign distribution"...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth